small molecule

DSUVIA

SUFENTANIL CITRATE

Loss of exclusivityFebruary 2038latest FDA-listed patent expiry
CompanyVerticalSee this company's full patent-cliff portfolio

Drug detail

Brand nameDSUVIA
Active ingredientSUFENTANIL CITRATE
StrengthEQ 0.03MG BASE
Dosage formTABLET
RouteSUBLINGUAL
ModalitySmall molecule
FDA approvalNovember 2018
Marketing statusDISCN

Listed patents

PatentExpiresType
11672738February 2038product
8945592July 2031product
8202535October 2030use U-1351
8865743October 2030use U-1351
10896751March 2030product
12033733March 2030product
8574189March 2030product
11676691March 2030product
8778394January 2027use U-1351
9744129January 2027product
8252329January 2027product
10342762January 2027product
8252328January 2027product
8231900January 2027product
8778393January 2027use U-1351
9320710January 2027use U-1351
8226978January 2027product
8865211January 2027use U-1351
10245228January 2027product
10507180January 2027product
8535714January 2027product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DSUVIA patent cliff — loss of exclusivity February 2038 | CliffBio